SAGE Therapeutics (SAGE) Reports Q1 Net Loss of $122.1M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to SAGE Therapeutics (SAGE) Reports Q1 Net Loss of $122.1M

Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

May 3, 2022 6:30 AM EDT

Rolling NDA submission for zuranolone in MDD underway, with full submission expected to be completed in the second half of 2022, associated NDA submission in PPD planned for early 2023

Topline data from Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD on track for mid-2022

Six planned and ongoing Phase 2 studies across neuropsychiatry and neurology franchises, demonstrate focused execution across pipeline programs

Company leadership strengthened with appointment of Mark Pollack, M.D., as Senior Vice President, Medical Affairs

Conference call... More